Get startedLog in
    Picture of SciClone Pharmaceuticals (Holdings) logo

    6600 — SciClone Pharmaceuticals (Holdings) Income Statement

    0.000.00%
    hk flag iconLast trade - 00:00
    HealthcareSpeculativeMid Cap
    Balance sheetIncome statementCashflow
    Subscribe to view all data

    Annual income statement for SciClone Pharmaceuticals (Holdings), fiscal year end - December 31st, CNY millions except per share, conversion factor applied.

    2019
    December 31st
    2020
    December 31st
    2021
    December 31st
    2022
    December 31st
    2023
    December 31st
    Period Length:12 M12 M12 M12 M12 M
    Source:PROSPECTUSARSARSARSARS
    Standards:
    IFRS
    IFRS
    IFRS
    IFRS
    IFRS
    Status:FinalFinalFinalFinalFinal
    Revenue
    Total Revenue1,7081,9192,5182,7503,156
    Cost of Revenue
    Gross Profit1,3151,4901,9332,0702,356
    Selling / General / Administrative Expenses
    Research And Development
    Depreciation and Amortization
    Unusual Expense / Income
    Other Operating Expenses
    Total Operating Expenses1,0581,0841,4601,7991,951
    Operating Profit6508351,0589511,205
    Total Net Non Operating Interest Income / Expense
    Net Income Before Taxes6618171,0269401,217
    Provision for Income Taxes
    Net Income After Taxes6157549238551,122
    Net Income Before Extraordinary Items
    Net Income6157549238551,122
    Income Available to Common Shareholders Excluding Extraordinary Items
    Income Available to Common Shareholders Including Extraordinary Items
    Diluted Net Income6157549238551,122
    Diluted Weighted Average Shares
    Basic EPS Including Extraordinary Items
    Diluted EPS Including Extraordinary Items
    Diluted EPS Excluding Extraordinary Items
    Normalised Income Before Taxes
    Normalised Income After Taxes
    Normalised Income Available to Common Shareholders
    Diluted Normalised EPS0.9071.451.411.341.87
    Dividends per Share